Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.
Executive Summary
FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.
You may also be interested in...
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S
FDA Sees Risk Management Role For Sales Forces; Drug Safety Cmte. Coming
FDA views pharmaceutical sales forces and promotion budgets as resources for risk management